Search Result
Results for "
Carboxamides
" in MedChemExpress (MCE) Product Catalog:
2
Biochemical Assay Reagents
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-138698
-
|
Deubiquitinase
|
Others
|
FT206 is an inhibitor of carboxamides as ubiquitin-specific protrase extracted from patent WO 2020033707 A1, example 11-1 .
|
-
-
- HY-103592
-
|
Ceramidase
|
Cancer
|
ARN14974, a benzoxazolone carboxamide, is a potent and systemically active inhibitors of intracellular acid ceramidase (IC50=79 nM) .
|
-
-
- HY-17520
-
MTF-753
|
Fungal
|
Infection
|
Penthiopyrad (MTF-753) is a chiral carboxamide antifungal agent with a broad spectrum of fungicidal activity. Penthiopyrad can be used for controlling foliar and soil-borne plants diseases on a broad range of agricultural crops and turfgrass .
|
-
-
- HY-147416
-
BI 1029539; GS-248; OX-MPI
|
PGE synthase
|
Infection
Cancer
|
Vipoglanstat (BI 1029539), a carboxamide, is a potent and selective, non-peptide and orally active small molecular inhibitor of human prostaglandin E synthase 1 (mPGES-1). Vipoglanstat also has anti-inflammatory activity .
|
-
-
- HY-W012921
-
-
-
- HY-163407
-
|
Galectin
|
Cancer
|
Galectin-3-IN-4 (compound 5) is a carboxamide analog. Galectin-3-IN-4 is a potent, selective, and orally bioavailable inhibitor of human and mouse galectin-3, with IC50 values of 21 and 167 nM for hGal-3 and mGal-3, respectively. Galectin-3-IN-4 has IC50 values of 1580 and 2750 nM for hGal-1 and hGal-9, respectively .
|
-
-
- HY-148766
-
|
Others
|
Metabolic Disease
|
VU661, a phenazine carboxamide, is a modulator of circadian rhythms to produce a period lengthening of the circadian rhythm. VU661 is a redox-active small molecule .
|
-
-
- HY-158987
-
APBADP
|
Endogenous Metabolite
|
Metabolic Disease
|
Adenosine phosphonobutyric, 2'(3'), 5'-diposphate (APBADP) is a potent Bacillus subtilis and human adenylosuccinate lyase (ASL) inhibitor. Adenosine phosphonobutyric, 2'(3'), 5'-diposphate also is a competitive succinylaminoimidazole carboxamide ribotide (SAICAR) inhibitor .
|
-
-
- HY-17520R
-
|
Fungal
|
Infection
|
Penthiopyrad (Standard) is the analytical standard of Penthiopyrad. This product is intended for research and analytical applications. Penthiopyrad (MTF-753) is a chiral carboxamide antifungal agent with a broad spectrum of fungicidal activity. Penthiopyrad can be used for controlling foliar and soil-borne plants diseases on a broad range of agricultural crops and turfgrass .
|
-
-
- HY-W017413
-
-
-
- HY-41461R
-
|
Endogenous Metabolite
|
Others
|
5-Amino-3H-imidazole-4-Carboxamide (Standard) is the analytical standard of 5-Amino-3H-imidazole-4-Carboxamide. This product is intended for research and analytical applications. 5-Amino-3H-imidazole-4-Carboxamide (AICA) is an important precursor for the synthesis of purines in general and of the nucleobases adenine and guanine in particular.
|
-
-
- HY-41461AR
-
|
Biochemical Assay Reagents
|
Others
|
5-Amino-3H-imidazole-4-carboxamide (hydrochloride) (Standard) is the analytical standard of 5-Amino-3H-imidazole-4-carboxamide (hydrochloride). This product is intended for research and analytical applications. 5-Amino-3H-imidazole-4-carboxamide hydrochloride is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
|
-
-
- HY-133157
-
5-Formamidoimidazole-4-carboxamide ribotide
|
DNA/RNA Synthesis
|
Others
|
FAICAR (5-Formamidoimidazole-4-carboxamide ribotide) is a purine nucleotide.
|
-
-
- HY-113472
-
-
-
- HY-13010
-
ABR-215062
|
NF-κB
Apoptosis
|
Inflammation/Immunology
|
Laquinimod (ABR-215062), an orally available carboxamide derivative, is a potent immunomodulator which prevents neurodegeneration and inflammation in the central nervous system. Laquinimod reduces astrocytic NF-κB activation to protect from Cuprizone-induced demyelination. Laquinimod has?the?potential?for relapsing remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS; RRMS or CPMS) as well as neurodegenerative diseases?research .
|
-
-
- HY-W062904
-
ABR-215062 sodium
|
NF-κB
Apoptosis
|
Neurological Disease
Inflammation/Immunology
|
Laquinimod (ABR-215062) sodium, an orally available carboxamide derivative, is a potent immunomodulator which prevents neurodegeneration and inflammation in the central nervous system. Laquinimod sodium reduces astrocytic NF-κB activation to protect from Cuprizone-induced demyelination. Laquinimod sodium has the potential for relapsing remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS; RRMS or CPMS) as well as neurodegenerative diseases research .
|
-
-
- HY-15736
-
|
Sodium Channel
|
Neurological Disease
|
Sodium Channel inhibitor1, one of 3-Oxoisoindoline-1-carboxamides, is a novel and selective voltage-gated sodium channel for pain treatment.
|
-
-
- HY-118245
-
|
Cannabinoid Receptor
|
|
APP-FUBINACA is a cannabinoid receptor agonist and a derivative of phenylalaninamide-based indazole-3-carboxamide. APP-FUBINACA exhibits neurostimulatory effects .
|
-
-
- HY-41461
-
5-Aminoimidazole-4-carboxamide; AICA
|
Endogenous Metabolite
|
Others
|
5-Amino-3H-imidazole-4-Carboxamide (AICA) is an important precursor for the synthesis of purines in general and of the nucleobases adenine and guanine in particular.
|
-
-
- HY-156021
-
|
Bacterial
|
Infection
|
Antitubercular agent-40 (compound 93) is a thieno[2,3-b]quinoline-2-carboxamide compound with potential antitubercular activity .
|
-
-
- HY-13010R
-
|
NF-κB
Apoptosis
|
Inflammation/Immunology
|
Laquinimod (Standard) is the analytical standard of Laquinimod. This product is intended for research and analytical applications. Laquinimod (ABR-215062), an orally available carboxamide derivative, is a potent immunomodulator which prevents neurodegeneration and inflammation in the central nervous system. Laquinimod reduces astrocytic NF-κB activation to protect from Cuprizone-induced demyelination. Laquinimod has the potential for relapsing remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS; RRMS or CPMS) as well as neurodegenerative diseases research .
|
-
-
- HY-41461A
-
5-Aminoimidazole-4-carboxamide hydrochloride; AICA hydrochloride
|
Biochemical Assay Reagents
|
Others
|
5-Amino-3H-imidazole-4-carboxamide hydrochloride is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
|
-
-
- HY-118699
-
|
Fungal
|
Infection
|
Indole-3-thio carboxamide is an antifungal agent. Indole-3-thio carboxamide is a biotransformation product of Camalexin (HY-119502) by plant pathogenic fungi Botrytis cinerea .
|
-
-
- HY-13907
-
TCS 359
1 Publications Verification
|
FLT3
|
Cancer
|
TCS 359, a 2-acylaminothiophene-3-carboxamide, is a potent and selective FLT3 inhibitor with an IC50 of 42 nM. TCS 359 inhibits MV4-11 cell proliferation with an IC50 of 340 nM .
|
-
-
- HY-128337
-
|
Parasite
|
Infection
|
AN7973 is the 6-carboxamide benzoxaborole, blocks intracellular parasite development and inhibits Cryptosporidium growth. AN7973 is orally active, possesses favorable safety, stability, and PK parameters, and is an exciting agent candidate for treating cryptosporidiosis.
|
-
-
- HY-106048
-
5-Hydroxy-1H-imidazole-4-carboxamide; SM-108
|
Nucleoside Antimetabolite/Analog
|
Others
|
Bredinin aglycone (5-Hydroxy-1H-imidazole-4-carboxamide) is a purine nucleotide analogue. Bredinin aglycone can be used to examine the efficiency of catalysts for the preparation of purine nucleotide analogues .
|
-
-
- HY-119415
-
ICN-17261
|
Others
|
Others
|
Levovirin (ICN-17261) is a potent 1-β-aminopyrazole-3-carboxamide that activates human T cells to secrete type 1 cytokines comparable to ribavirin. Levovirin shows promising immunomodulatory properties .
|
-
-
- HY-107981
-
|
Antifolate
|
Cancer
|
LSN 3213128 is a selective, nonclassical, orally bioavailable antifolate with potent and specific inhibitory activity for aminoimidazole-4-carboxamide ribonucleotide formyltransferase (AICARFT), with IC50 of 16 nM for AICARFT enzyme inhibiton and 19 nM in cells. Anti-tumor activity .
|
-
-
- HY-152318
-
|
Nucleoside Antimetabolite/Analog
|
Others
|
Adenosine-2-carboxamide is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
-
- HY-151938
-
|
HIV
|
Infection
|
Reverse transcriptase-IN-3 is a pyrimidine-5-carboxamide derivative, acts as an inhibitor of HIV-1. Reverse transcriptase-IN-3 shows potent activity against the HIV-1 wild-type and mutant strains .
|
-
-
- HY-100162
-
-
-
- HY-114570
-
NSC 286193; Riboxamide
|
Nucleoside Antimetabolite/Analog
Orthopoxvirus
|
Infection
Cancer
|
Tiazofurin (NSC 286193) is a synthetic nucleoside analogue with antineoplastic activity. Tiazofurin is anabolized intracellularly to tiazole-4-carboxamide adenine dinucleotide (TAD), a potent inhibitor of IMP dehydrogenase (IMPDH) . Tiazofurin also has anti-orthopoxvirus and anti-variola activities .
|
-
-
- HY-W702068
-
Metabolite D hydrochloride
|
Biochemical Assay Reagents
|
Others
|
7-Hydroxy-1-methyl-N-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-1H-indazole-3-carboxamide (Metabolite D) hydrochloride is a biological molecule.
|
-
-
- HY-150252A
-
|
Others
|
Cancer
|
ATIC-IN-1 (compound 14) acetate is an inhibitor targeting to Aminoimidazole carboxamide ribonucleotide transformylase/inosine monophosphate cyclohydrolase (ATIC) dimerization with a Ki value of 685 nM. ATIC dimerization is crucial for its aminoimidazole carboxamide ribonucleotide (AICAR) transformylase activity. ATIC-IN-1 acetate exhibits anti-tumor activity via reduction in cell numbers and cell division rates .
|
-
-
- HY-150252
-
|
Others
|
Cancer
|
ATIC-IN-1(compound 14) is an inhibitor targeting to Aminoimidazole carboxamide ribonucleotide transformylase/inosine monophosphate cyclohydrolase (ATIC) dimerization with a Ki value of 685 nM. ATIC dimerization is crucial for its aminoimidazole carboxamide ribonucleotide (AICAR) transformylase activity. ATIC-IN-1 exhibits anti-tumor activity via reduction in cell numbers and cell division rates .
|
-
-
- HY-135830
-
|
Aryl Hydrocarbon Receptor
|
Cancer
|
AHR antagonist 4 is a 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamide compound and a potent aryl hydrocarbon receptor (AHR) antagonist extracted from patent WO2018146010A1, example 293, has an IC50 of 82.2 nM. AHR antagonist 4 has anti-cancer effects .
|
-
-
- HY-148038
-
|
5-HT Receptor
|
Neurological Disease
|
5-HT3 antagonist 5 is a quinoxalin-2-carboxamide compound, a 5-HT3 receptor antagonist. 5-HT3 antagonist 5 exerts antagonism on 5-HT3 agonist and 2-methyl-5-HT, and shows anti-depressant effect in mice .
|
-
-
- HY-152685
-
|
Nucleoside Antimetabolite/Analog
|
Others
|
4-Amino-1-(β-D-ribofurano syl)-7H-pyrrolo [2.3-d] pyrimidine-5-carboxamide is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
-
- HY-W956235
-
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
(2S,4R)-1-((S)-3,3-Dimethyl-2-(2-(piperazin-1-yl)acetamido)butanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide is an E3 ligase ligand-linker conjugate.
|
-
-
- HY-159487
-
|
E3 Ligase Ligand-Linker Conjugates
|
Cancer
|
(2S,4R)-4-Hydroxy-1-((S)-2-(6-(4-methoxyphenyl)spiro[3.3]heptane-2-carboxamido)-3,3-dimethylbutanoyl)-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide is an E3 ligase ligand-linker conjugate.
|
-
-
- HY-149082
-
|
Leukotriene Receptor
|
Inflammation/Immunology
|
LTB4 antagonist 1, a carboxamide-acid compound, is a potent Leukotriene B4 (LTB4) antagonist with an IC50 of 288 nM. LTB4 antagonist 1 has significant anti-inflammatory properties .
|
-
-
- HY-149365
-
|
Salt-inducible Kinase (SIK)
|
Inflammation/Immunology
|
SIKs-IN-1 (compound 8h), a pyrimidine-5-carboxamide derivative, is a Salt-inducible kinases (SIKs) inhibitor. SIKs regulates the transformation of M1/M2 macrophages, involving in inflammation process. SIKs-IN-1 inhibits SIK activity, up-regulates anti-inflammatory cytokine IL-10, but down-regulates pro-inflammatory cytokine IL-12. SIKs-IN-1 shows excellent anti-inflammatory effects in a DSS-induced colitis model .
|
-
-
- HY-106628
-
|
COX
|
Inflammation/Immunology
|
Sudoxicam is a reversible and orally active COX antagonist and a non-steroidal anti-inflammatory drug (NSAID) from the enol-carboxamide class. Sudoxicam has potent anti-inflammatory, anti-edema and antipyretic activity .
|
-
-
- HY-149083
-
|
Leukotriene Receptor
|
Inflammation/Immunology
|
LTB4 antagonist 2, a carboxamide-acid compound, is an antagonist of leukotriene B4 (LTB4) with potentially anti-inflammatory activity. LTB4 antagonist 2 shows good affinity for the LTB4 receptor with IC50 of 439 nM .
|
-
-
- HY-124260
-
|
p38 MAPK
|
Inflammation/Immunology
|
SB-204900 is an oxane carboxamide that can be isolated from the hexane extract of Clausena lansium. SB-204900 significantly inhibited phosphorylation of p38 MAPK. SB-204900 has anti-inflammatory activity .
|
-
-
- HY-P4154
-
ALM-488
|
Fluorescent Dye
|
Neurological Disease
Cancer
|
Bevonescein (ALM-488) is a novel, intravenously-administrated fluorescein-conjugated peptide that binds nerve-associated connective tissue, labels peripheral nerves under real-time fluorescence imaging (FL) in living mice and human ex vivo nerve tissue. Bevonescein is a peptide-linked tracer which fluorescently labeled both intact and degenerated nerves .
|
-
-
- HY-P1103A
-
|
CXCR
|
Cancer
|
CTCE-9908 TFA is a potent and selective CXCR4 antagonist. CTCE-9908 TFA induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .
|
-
-
- HY-P1103
-
|
CXCR
|
Cancer
|
CTCE-9908 is a potent and selective CXCR4 antagonist. CTCE-9908 induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .
|
-
-
- HY-118911
-
|
ATM/ATR
|
Cancer
|
ATM Inhibitor-10 (compound 74), a 3-quinoline carboxamide, is a highly selective and orally active ATM inhibitor (IC50: 0.6 nM). ATM Inhibitor-10 has anti-tumor activity in SW620 xenograft models. ATM Inhibitor-10 is synergistic with Top I inhibitors .
|
-
-
- HY-P2231A
-
MEDI0382 acetate
|
GCGR
|
Metabolic Disease
|
Cotadutide (MEDI0382) acetate is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC50 values of 6.9 pM and 10.2 pM, respectively. Cotadutide acetate exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide acetate can be used in the research of obesity and type 2 diabetes (T2D) .
|
-
- HY-104027
-
-
- HY-162813
-
|
PROTACs
Epigenetic Reader Domain
|
Cancer
|
PROTAC SMARCA2/4-degrader-25 (compound 7d) is a PROTAC targeting SMARCA2/4. PROTAC SMARCA2/4-degrader-25 is composed of E3 ligase (2S,4R)-4-Hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (HY-W998248) (blue part), PROTAC Linker (S)-2-Amino-3,3-dimethylbutanoic acid (HY-59140) (black part), and target protein ligand SMARCA2/4-ligand-3 (HY-162814) (red part). The conjugate of E3 ubiquitin ligase ligand + Linker is (S,R,S)-AHPC (HY-125845) [1] .
|
-
- HY-151813
-
|
Fluorescent Dye
|
Cancer
|
NNMT-IN-4 (compound 38) is a selective, uncompetitive and membrane permeability nicotinamide N-methyltransferase (NNMT) inhibitor with IC50 values of 42 and 38 nM in vitro biochemical and cell-based assays, respectively. NNMT-IN-4 shows favorable PK/PD and safety profiles as well as excellent oral bioavailability and pharmaceutical properties. NNMT-IN-4 can be used as a vivo chemical probe of NNMT .
|
-
- HY-P2231
-
MEDI0382
|
GCGR
|
Metabolic Disease
|
Cotadutide (MEDI0382) is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC50 values of 6.9 pM and 10.2 pM, respectively. Cotadutide exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide can be used in the research of obesity and type 2 diabetes (T2D) .
|
-
- HY-15738
-
GNF-5
3 Publications Verification
|
Bcr-Abl
|
Cancer
|
GNF-5, the N-hydroxyethyl carboxamide analog of GNF-2, is an orally active Bcr-Abl inhibitor. GNF-5 has Bcr-Abl inhibition activity with an IC50 value of 0.22 μM. GNF-5 has good favorable pharmacokinetic properties. GNF-5 can be used for the research of kinds of cancer including chronic myelogenous leukemia (CML) and breast cancer .
|
-
- HY-132994
-
|
Others
|
Others
|
TVD-0003510 is a carboxamide derivative, and involves in synthesis of (2-((6-(2-aminopyrimidine-5-carboxamido)-8-methoxy-3,4-dihydro-2H-pyrimido[1,2-c]quinazolin-9-yl)oxy)ethyl)piperazine-l-carboxylate (C51), as a part of tert-butyl2-(4-hydroxyphenyl)acetate .
|
-
- HY-143295
-
|
Pim
Apoptosis
|
Cancer
|
Pim-1 kinase inhibitor 1 is a Pim-1 kinase inhibitor with an IC50 of 0.11 μM for Pim-1 kinase. Pim-1 kinase inhibitor 1 shows anticancer activity to several cancer cell lines by promotes cell apoptosis. Pim-1 kinase inhibitor 1 can be used for the research of cancer .
|
-
- HY-162815
-
|
PROTACs
Epigenetic Reader Domain
|
Cancer
|
PROTAC SMARCA2/4-degrader-26 (compound 6) is a PROTAC targeting SMARCA2/4. SMARCA2 and SMARCA4 are genes and cancer targets with complementary functions that catalyze nucleosome movement. PROTAC SMARCA2/4-degrader-25 is composed of PROTAC target protein ligand 2-(4-(3-Amino-6-(2-hydroxyphenyl)pyridazin-4-yl)piperazin-1-yl)acetic acid (HY-46618) (red part), E3 ligase ligand (2S,4R)-4-Hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (HY-W998248) (blue part), PROTAC linker (S)-2-Amino-3,3-dimethylbutanoic acid (HY-59140) (black part), and the conjugate composed of E3 ubiquitin ligase ligand + Linker is (S,R,S)-AHPC (HY-125845) [1] .
|
-
- HY-P1321
-
1229U91; GW1229
|
Neuropeptide Y Receptor
|
Neurological Disease
|
GR231118, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide Y Y receptor with a pKi of 10.4. GR231118 a potent agonist at the human neuropeptide Y Y4 receptor (pEC50=8.6; pKi=9.6) and a weak agonist at the human and rat neuropeptide YY2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide Y Y6 receptor (pKi= 8.8) .
|
-
- HY-P1321A
-
1229U91 TFA; GW1229 TFA
|
Neuropeptide Y Receptor
|
Neurological Disease
|
GR231118 TFA, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide YY receptor with a pKi of 10.4. GR231118 a potent agonist at the human neuropeptide YY4 receptor (pEC50=8.6; pKi=9.6) and a weak agonist at the human and rat neuropeptide Y Y2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide YY6 receptor (pKi= 8.8) .
|
-
- HY-161712
-
|
Others
|
Cancer
|
Nampt-IN-12 (compound 9) is a derivative of N-Pyridinylthiophene carboxamide, exhibiting activity against peripheral nerve sheath tumor cells. Nampt-IN-12 is metabolized via the enzymes NAMPT and NMNAT1, both integral to the NAD salvage pathway, into an adenosine diphosphate (AD) derivative, which is an analog of NAD and capable of inhibiting inosine monophosphate dehydrogenase (IMPDH), leading to the accumulation of inosine monophosphate (IMP) within cells. With its favorable ability to cross the blood-brain barrier, Nampt-IN-12 holds potential for research in cancers affecting both the central and peripheral nervous systems .
|
-
- HY-168066
-
|
Fungal
|
Infection
|
Antifungal agent 117 is a bis-pyrazole carboxamide derivative with antifungal activity, exhibiting an EC50 value of 11.58 mg/L against Sclerotinia sclerotiorum. Antifungal agent 117 increases cell membrane permeability, causing an imbalance in osmotic pressure inside and outside the cell, and induces the accumulation of reactive oxygen species (ROS), leading to oxidative damage to the cell membrane, resulting in leakage of cellular contents and eventually cell death. RNA sequencing analysis reveals that Antifungal agent 117 downregulates catalase genes and upregulates neutral ceramidase genes, disrupting cell membrane structure, accelerating sphingolipid metabolism, and promoting cell death. Antifungal agent 117 shows great potential in the fields of plant protection and antifungal infection .
|
-
Cat. No. |
Product Name |
Type |
-
- HY-41461A
-
5-Aminoimidazole-4-carboxamide hydrochloride; AICA hydrochloride
|
Biochemical Assay Reagents
|
5-Amino-3H-imidazole-4-carboxamide hydrochloride is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
|
-
- HY-41461AR
-
|
Biochemical Assay Reagents
|
5-Amino-3H-imidazole-4-carboxamide (hydrochloride) (Standard) is the analytical standard of 5-Amino-3H-imidazole-4-carboxamide (hydrochloride). This product is intended for research and analytical applications. 5-Amino-3H-imidazole-4-carboxamide hydrochloride is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
|
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-W012921
-
-
- HY-P4154
-
ALM-488
|
Fluorescent Dye
|
Neurological Disease
Cancer
|
Bevonescein (ALM-488) is a novel, intravenously-administrated fluorescein-conjugated peptide that binds nerve-associated connective tissue, labels peripheral nerves under real-time fluorescence imaging (FL) in living mice and human ex vivo nerve tissue. Bevonescein is a peptide-linked tracer which fluorescently labeled both intact and degenerated nerves .
|
-
- HY-P1103
-
|
CXCR
|
Cancer
|
CTCE-9908 is a potent and selective CXCR4 antagonist. CTCE-9908 induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .
|
-
- HY-P2231A
-
MEDI0382 acetate
|
GCGR
|
Metabolic Disease
|
Cotadutide (MEDI0382) acetate is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC50 values of 6.9 pM and 10.2 pM, respectively. Cotadutide acetate exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide acetate can be used in the research of obesity and type 2 diabetes (T2D) .
|
-
- HY-P2231
-
MEDI0382
|
GCGR
|
Metabolic Disease
|
Cotadutide (MEDI0382) is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC50 values of 6.9 pM and 10.2 pM, respectively. Cotadutide exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide can be used in the research of obesity and type 2 diabetes (T2D) .
|
-
- HY-P10026
-
LY-3457263
|
Peptides
|
Metabolic Disease
|
Nisotirotide (LY-3457263) is a PYY analog agonist studied in type 2 diabetes and obesity .
|
-
- HY-W017413
-
-
- HY-P1103A
-
|
CXCR
|
Cancer
|
CTCE-9908 TFA is a potent and selective CXCR4 antagonist. CTCE-9908 TFA induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .
|
-
- HY-P4757
-
|
Peptides
|
Others
|
N1-Glutathionyl-spermidine disulfide is a substrate of trypanothione reductase .
|
-
- HY-P1321
-
1229U91; GW1229
|
Neuropeptide Y Receptor
|
Neurological Disease
|
GR231118, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide Y Y receptor with a pKi of 10.4. GR231118 a potent agonist at the human neuropeptide Y Y4 receptor (pEC50=8.6; pKi=9.6) and a weak agonist at the human and rat neuropeptide YY2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide Y Y6 receptor (pKi= 8.8) .
|
-
- HY-P1321A
-
1229U91 TFA; GW1229 TFA
|
Neuropeptide Y Receptor
|
Neurological Disease
|
GR231118 TFA, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide YY receptor with a pKi of 10.4. GR231118 a potent agonist at the human neuropeptide YY4 receptor (pEC50=8.6; pKi=9.6) and a weak agonist at the human and rat neuropeptide Y Y2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide YY6 receptor (pKi= 8.8) .
|
Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
Cat. No. |
Product Name |
|
Classification |
-
- HY-152318
-
|
|
Nucleosides and their Analogs
|
Adenosine-2-carboxamide is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152685
-
|
|
Nucleosides and their Analogs
|
4-Amino-1-(β-D-ribofurano syl)-7H-pyrrolo [2.3-d] pyrimidine-5-carboxamide is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: